Intriguing combination therapies demonstrated that blockade of the myeloid checkpoint CD38 by daratumumab, a therapeutic Ab approved for multiple myeloma, invigorated the killing of acute lymphoblastic T-cell leukemia cells in vitro [153]. This evidence concerns the gene CD38 and plasma cell myeloma.